Cel-Sci Corporation
CEL-SCI Corp. is a late-stage biotechnology company focused on developing immune-system-based therapies for cancer and other diseases. Its lead program is Multikine, an investigational immunotherapy for head and neck cancer, which the company has advanced through a long Phase III development program and into manufacturing readiness for potential regulatory filings. CEL-SCI also owns the LEAPS technology platform, which it is using to develop CEL-4000 as a vaccine treatment for rheumatoid arthritis. The company currently has no approved commercial products and is still dependent on financing activities while it seeks regulatory approvals and potential licensing opportunities.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueMultikine is CEL-SCI's principal investigational product for head and neck cancer and the main focus of its clinical and regulatory work.
LEAPS is a platform technology used to generate next-generation immune-based candidates, including CEL-4000.
The company operates a dedicated biologics manufacturing facility and related development capabilities to support clinical supply and future commercialization.
Customers
CEL-SCI does not currently sell approved products to end customers, so its near-term 'customers' are primarily regulators, clinical investigators, and potential licensing or commercialization partners. The company’s most concrete commercial counterparty disclosed in the reports is Teva Pharmaceutical Industries, which has rights to market Multikine in Israel and Turkey if the product is approved. In the future, if Multikine is approved, the buyers would likely include hospitals, oncology treatment centers, and national or private payors that reimburse cancer therapies. For its platform assets, CEL-SCI is also positioning itself for licensing arrangements rather than direct broad-based product sales.
FDA, SFDA, and other agencies review Multikine and determine whether CEL-SCI can commercialize its products.
Teva and related affiliates hold territorial rights to market and sell Multikine in selected countries if approved.
Hospitals and oncology treatment centers would administer Multikine if it reaches market approval.
Government and private insurers would determine whether Multikine is covered and at what reimbursement level.
Pharmaceutical companies may license CEL-SCI technology or participate in future oncology indications.
Strategy
CEL-SCI's strategy is centered on completing the regulatory package for Multikine and converting years of clinical development into a potential first commercial product. A key priority is maintaining manufacturing readiness, as the company has invested in a dedicated facility and completed commissioning to support a planned BLA submission and future supply needs. The company is also broadening regulatory optionality by pursuing filings in multiple jurisdictions and by using regional partners such as Teva and Dallah Pharma to extend market access without building a large commercial organization. In parallel, CEL-SCI continues to fund operations primarily through equity issuance and warrants, reflecting a strategy of preserving development continuity until a licensing or approval event can create revenue.
Approval is the main path to first product revenue and validates the company's core asset.
A biologics launch requires validated production capacity and reliable clinical/commercial supply.
Partner-led commercialization reduces CEL-SCI's need for a large sales force and expands reach.
A second platform could reduce dependence on Multikine and create future partnering opportunities.
Geography
CEL-SCI is headquartered in the United States and its core development, regulatory, and manufacturing activities are centered there. The company is pursuing a U.S. Biologics License Application strategy for Multikine while also planning filings in Canada, the United Kingdom, Europe, and Saudi Arabia. Commercial rights have already been licensed in Israel, Turkey, Serbia, and Croatia through Teva and related affiliates, showing that the company is using regional partners to extend its reach. Because CEL-SCI has no meaningful product revenue yet, geography mainly affects regulatory pathways, clinical execution, and future commercialization optionality rather than current sales mix.
Risks
CEL-SCI faces substantial development-stage risk because its lead product is still investigational and has not been approved by the FDA or other regulators. The company is exposed to long and expensive clinical and regulatory timelines, and any delay or failure in the confirmatory study, BLA process, or foreign filings could materially defer commercialization. Even if approved, Multikine would still face reimbursement risk because payors may challenge pricing or decide the therapy is not cost-effective enough for coverage. As a small biotech with no meaningful product revenue, CEL-SCI also depends on external financing, so dilution, capital-market volatility, and liquidity constraints are major business risks. More broadly, the company is exposed to manufacturing validation risk, partner execution risk in licensed territories, and general biotech industry risks such as clinical failure, regulatory changes, and patent or exclusivity challenges.
The company has no approved products and depends on Multikine to create commercial revenue.
Exposure: Lead asset and primary value driver
Even approved biologics can face cost-effectiveness scrutiny and limited coverage.
Exposure: Future oncology commercialization
Operations have historically been funded through equity, warrants, and loans.
Exposure: Corporate liquidity and development funding
Biologics require validated production processes and reliable supply before launch.
Exposure: Multikine clinical and commercial supply
Commercial rights in some countries depend on third-party partners' regulatory and sales efforts.
Accounting
Judgemental itemsClinical trial and manufacturing costs are expensed as incurred and can swing with program activity.
Impact: Affects operating loss and period-to-period comparability
The company leases a dedicated facility, so lease term and discount-rate assumptions matter.
Impact: Affects balance sheet lease assets/liabilities and interest/occupancy expense
Equity awards are used to pay employees and consultants, creating non-cash expense.
Impact: Affects reported G&A expense and dilution analysis
The company depends on external financing to fund ongoing development.
Impact: Important for evaluating solvency and future dilution risk
Similar listed companies
Publicly listed companies with a comparable business focus.
MoonLake Immunotherapeutics
MLTX · Pharmaceutical Preparations
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing SLK, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F…
Century Therapeutics, Inc.
IPSC · Biological Products, (No Diagnostic Substances)
Celcuity Inc.
CELC · Services-Medical Laboratories
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Purple Biotech Ltd
PPBT · Pharmaceutical Preparations
Last updated: 11/08/2026